GlassScriptPhysician profile
Amy E Shirley
NPI 1770068330
$5,231.51
in general payments reported to CMS, 2019-2025
45 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $752 · 2023: $1,115 · 2024: $1,531 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,352 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.35 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $575.18 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $374.02 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Novo Nordisk INC | $352.91 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $294.67 | 2022-2025 | Mounjaro, Zepbound, Reyvow |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.38 | 2021-2025 | Jardiance, Ofev |
| Pfizer INC. | $160.97 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $151.63 | 2023-2025 | Rexulti |
| Corium, LLC | $146.94 | 2024-2025 | Azstarys |
| Dexcom, INC. | $120.57 | 2022-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $119.82 | 2023-2025 | Repatha, Repatha, Otezla |
| Corcept Therapeutics | $96.07 | 2024-2025 | Korlym |
| Verona Pharma, INC. | $90.43 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $86.82 | 2021-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $77.58 | 2022-2025 | Veozah, Myrbetriq |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Shirley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.